This HTML5 document contains 82 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/national-drug-code-directory/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/chemspider/
n21http://bio2rdf.org/drugbank:
n29http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/wikipedia/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/kegg-compound/
n11http://www.drugs.com/cdi/
n17http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01204/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01204
rdf:type
n5:Drug
n5:description
An anthracenedione-derived antineoplastic agent. [PubChem]
n5:dosage
n22:271B557D-363D-11E5-9242-09173F13E4C5 n22:271B557E-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16750460
n5:group
approved investigational
n5:halfLife
75 hours
n5:indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
owl:sameAs
n15:DB01204 n21:DB01204
dcterms:title
Mitoxantrone
adms:identifier
n4:4067 n18:Mitoxantrone n23:46504608 n24:PA450526 n25:4212 n26:C11195 n27:0703-4685-01 n28:DB01204 n29:50729
n5:mechanismOfAction
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.
n5:packager
n7:271B5576-363D-11E5-9242-09173F13E4C5 n7:271B5577-363D-11E5-9242-09173F13E4C5 n7:271B556F-363D-11E5-9242-09173F13E4C5 n7:271B5570-363D-11E5-9242-09173F13E4C5 n7:271B5573-363D-11E5-9242-09173F13E4C5 n7:271B5571-363D-11E5-9242-09173F13E4C5 n7:271B5572-363D-11E5-9242-09173F13E4C5 n7:271B5574-363D-11E5-9242-09173F13E4C5 n7:271B5575-363D-11E5-9242-09173F13E4C5 n7:271B5578-363D-11E5-9242-09173F13E4C5
n5:synonym
Mitoxantrona Mitoxantronum 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione Mitoxantrone
n5:toxicity
Severe leukopenia with infection.
n5:volumeOfDistribution
* 1000 L/m2
n12:hasAHFSCode
n13:10-00-00
n5:proteinBinding
78%
n5:salt
n5:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Mitoxantrone.htm
n8:hasConcept
n9:M0013954
foaf:page
n11:mitoxantrone.html n17:mitoxantrone.htm
n5:IUPAC-Name
n6:271B5583-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5589-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5588-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5585-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5586-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5587-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5581-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B557F-363D-11E5-9242-09173F13E4C5 n6:271B5599-363D-11E5-9242-09173F13E4C5 n6:271B5582-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5580-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n20:L01DB07
n5:H-Bond-Acceptor-Count
n6:271B558F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5590-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B558A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B558B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B558D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B558C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B558E-363D-11E5-9242-09173F13E4C5
n5:absorption
Poorly absorbed following oral administration
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
65271-80-9
n5:category
n5:clearance
* 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2] * 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2] * 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
n5:containedIn
n19:271B5579-363D-11E5-9242-09173F13E4C5 n19:271B557C-363D-11E5-9242-09173F13E4C5 n19:271B557A-363D-11E5-9242-09173F13E4C5 n19:271B557B-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5595-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5597-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5598-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5594-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5593-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5596-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5584-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5591-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5592-363D-11E5-9242-09173F13E4C5